Onesource Specialty Pharma Share Price Today (ONESOURCE)
TODAY IN ONE LINE
ONESOURCE rose 2.5% on above-average volume (2.1x avg), outperforming Nifty's -0.0% move.
With a market cap of ₹19,856.65 Cr., it trades at a P/E of -407.42. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Onesource Specialty Pharma flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 21.4%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 95.3% YoY
Latest Onesource Specialty Pharma News
What changed recently?
Recent events, corporate actions, and announcements.
Onesource Specialty Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Onesource Specialty Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Onesource Specialty Pharma Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Onesource Specialty Pharma Limited — derived from the live tape, not yesterday's close.
Onesource Specialty Pharma Limited last traded at ₹1,731.3 with an intraday range of ₹1,672.1–₹1,750 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1731.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1919.30 | +188.00 | +10.86% |
| R3 | 1841.40 | +110.10 | +6.36% |
| R2 | 1795.70 | +64.40 | +3.72% |
| R1 | 1763.50 | +32.20 | +1.86% |
| PIVOT | 1717.80 | -13.50 | -0.78% |
| CURRENT | 1731.30 | — | — |
| S1 | 1685.60 | -45.70 | -2.64% |
| S2 | 1639.90 | -91.40 | -5.28% |
| S3 | 1607.70 | -123.60 | -7.14% |
| S4 | 1529.80 | -201.50 | -11.64% |
ONESOURCE is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1672.1–₹1704.5
Trading Above opening range, showing Bullishness
Onesource Specialty Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Onesource Specialty Pharma Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Onesource Specialty Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹19,856.65 Cr. and reported EPS of ₹-6.45.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,445 | 1,422 ▼ 1.6% |
| Sales Growth YoY %Derived | — | -1.61% |
| Other Income | 17 | 15 ▼ 14.0% |
| Total Income | 1,462 | 1,437 ▼ 1.8% |
| 435 | 445 ▲ 2.2% | |
| Gross ProfitDerived | 1,010 | 977 ▼ 3.3% |
| Gross Margin %Derived | 69.89% | 68.72% |
| 543 | 673 ▲ 23.8% | |
| EBITDA (Operating Profit)Derived | 467 | 304 ▼ 34.8% |
| OPM %Derived | 32.29% | 21.40% |
| 329 | 391 ▲ 18.8% | |
| Profit Before Tax (PBT) | -67 | -92 ▼ 37.1% |
| -50 | -18 ▲ 63.5% | |
| Effective Tax %Derived | 74.23% | 19.75% |
| Profit/Loss from Discontinued Ops | -1 | — ▲ 100.0% |
| Total Profit for Period | -17 | -74 ▼ 327.1% |
| Net Profit (Owner's PAT)Derived | -17 | -74 ▼ 327.1% |
| Net Profit Margin %Derived | -1.20% | -5.19% |
| PAT Growth YoY %Derived | — | -327.08% |
| Earnings Per Share (EPS ₹) | -1.57 | -6.44 ▼ 310.2% |
| Diluted Shares Outstanding (Cr) | 11 | 11 ▲ 0.2% |
| Other Comprehensive Income (Net of Tax) | -3 | 16 ▲ 605.8% |
| Total Expenses (incl. D&A & Interest) | 1,529 | 1,529 ▼ 0.1% |
| Material Cost % of RevenueDerived | 22.72% | 30.72% |
| Employee Cost % of RevenueDerived | 14.90% | 17.04% |
| Other Cost % of RevenueDerived | 22.70% | 30.28% |
| Interest Coverage (x)Derived | 1.16x | 0.21x |
| Period | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 1,445 | 1,422 ▼ 1.6% | |
| Sales Growth YoY %Derived | — | -1.61% | |
| Other Income | 17 | 15 ▼ 14.0% | |
| Total Income | 1,462 | 1,437 ▼ 1.8% | |
435 | 445 ▲ 2.2% | ||
| Gross ProfitDerived | 1,010 | 977 ▼ 3.3% | |
| Gross Margin %Derived | 69.89% | 68.72% | |
543 | 673 ▲ 23.8% | ||
| EBITDA (Operating Profit)Derived | 467 | 304 ▼ 34.8% | |
| OPM %Derived | 32.29% | 21.40% | |
329 | 391 ▲ 18.8% | ||
| Profit Before Tax (PBT) | -67 | -92 ▼ 37.1% | |
-50 | -18 ▲ 63.5% | ||
| Effective Tax %Derived | 74.23% | 19.75% | |
| Profit/Loss from Discontinued Ops | -1 | — ▲ 100.0% | |
| Total Profit for Period | -17 | -74 ▼ 327.1% | |
| Net Profit (Owner's PAT)Derived | -17 | -74 ▼ 327.1% | |
| Net Profit Margin %Derived | -1.20% | -5.19% | |
| PAT Growth YoY %Derived | — | -327.08% | |
| Earnings Per Share (EPS ₹) | -1.57 | -6.44 ▼ 310.2% | |
| Diluted Shares Outstanding (Cr) | 11 | 11 ▲ 0.2% | |
| Other Comprehensive Income (Net of Tax) | -3 | 16 ▲ 605.8% | |
| Total Expenses (incl. D&A & Interest) | 1,529 | 1,529 ▼ 0.1% | |
| Material Cost % of RevenueDerived | 22.72% | 30.72% | |
| Employee Cost % of RevenueDerived | 14.90% | 17.04% | |
| Other Cost % of RevenueDerived | 22.70% | 30.28% | |
| Interest Coverage (x)Derived | 1.16x | 0.21x |
Onesource Specialty Pharma segment analysis : revenue and profit mix.
Disclosed business segments at Onesource Specialty Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Onesource Specialty Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Onesource Specialty Pharma Limited.
Our AI distills the core fundamental drivers supporting Onesource Specialty Pharma Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Onesource Specialty Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin of 21.40% quarterly demonstrates strong cost discipline and operational efficiency.
Debt-to-equity ratio of 0.26x provides substantial financial flexibility for strategic expansion.
Niche CDMO positioning in cell-gene therapy and RNA therapeutics enables premium pricing potential.
Institutional ownership at 35.30% reflects growing confidence in long-term business model viability.
Global operations across Ireland, US, and India diversify revenue streams beyond domestic market.
Key Risks.
Latest quarterly EPS declined 95.30% YoY despite revenue growth, signaling severe earnings deterioration.
Negative net margin of -5.19% annually indicates fundamental unprofitability at operational scale.
Extreme P/E valuation of -256.44x reflects negative earnings and severe market skepticism.
Operating cash flow negative ₹399.21 Cr in latest quarter shows weak cash conversion.
Zero dividend yield provides no shareholder income or capital return mechanism whatsoever.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Onesource Specialty Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Onesource Specialty Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Onesource Specialty Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Onesource Specialty Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Onesource Specialty Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Onesource Specialty Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Onesource Specialty Pharma Limited stood at 47.2% of traded volume, against a 20-day average of 48.0%.
Onesource Specialty Pharma announcements: results, concalls, ratings, M&A.
Filings Onesource Specialty Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Onesource Specialty Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 143 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
OneSource Specialty Pharma Limited has informed the Exchange about Link of Recording
Updates
Onesource Specialty Pharma Limited has informed the Exchange regarding 'Allotment of ESOPs'.
Press Release
Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated July 24, 2026, titled "OneSource announces strong Q1FY27…
Change in Management
Onesource Specialty Pharma Limited has informed the Exchange about change in Management of the Company
Outcome of Board Meeting
Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Investor decks & rating reports.
Onesource Specialty Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Onesource Specialty Pharma has declared, sequenced by announce and record date.
Onesource Specialty Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Onesource Specialty Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Onesource Specialty Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Onesource Specialty Pharma insider activity below tracks 10 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Pronomz Ventures LLP | Insider | 13 Jun 2025 | sell | −51.03 L | ₹1,008.77 Cr. | ₹1,977.00 |
| Sajitha Pillai | Insider | 06 Feb 2025 | sell | −5.0 K | ₹77.39 L | ₹1,547.84 |
| Sajitha Pillai | Insider | 05 Feb 2025 | sell | −7.5 K | ₹1.15 Cr. | ₹1,532.06 |
| Hemalatha Pillai | Insider | 03 Feb 2025 | sell | −18.0 K | ₹2.62 Cr. | ₹1,453.07 |
| Neeraj Sharma | Insider | 03 Feb 2025 | sell | −20.0 K | ₹2.97 Cr. | ₹1,487.15 |
| Vineetha Mohankumar Pillai | Insider | 31 Jan 2025 | sell | −47.5 K | ₹7.44 Cr. | ₹1,565.38 |
| Padmakumar Karunakaran Pillai | Insider | 31 Jan 2025 | sell | −50.0 K | ₹7.79 Cr. | ₹1,558.73 |
| Hemalatha Pillai | Insider | 31 Jan 2025 | sell | −12.0 K | ₹1.9 Cr. | ₹1,579.62 |
| Tenshi Pharmaceuticals Private Limited | Insider | 31 Jan 2025 | sell | −33.01 L | ₹505.62 Cr. | ₹1,531.74 |
| Pronomz Ventures LLP | Insider | 31 Jan 2025 | sell | −5.83 L | ₹90 Cr. | ₹1,545.00 |
About Onesource Specialty Pharma Limited: business, sector, key facts.
What Onesource Specialty Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Onesource Specialty Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ONESOURCE, BSE: 544292.
ONESOURCE Specialty Pharma Limited is a biopharmaceutical company headquartered in Bengaluru, India, focusing on the research, development, manufacturing, and commercialization of biological drug products. Their primary market is both within India and internationally. The company's core business revolves around providing high-quality biologics in various injectable formats, catering to a broad spectrum of pharmaceutical needs.
A significant aspect of ONESOURCE's operations is its comprehensive contract development and manufacturing organization (CDMO) services. These services span the entire lifecycle of drug development, from the preclinical and clinical phases all the way through to the commercial supply of biologics. This end-to-end approach offers clients a streamlined and integrated solution for bringing their biopharmaceutical products to market.
Beyond its CDMO capabilities, ONESOURCE also boasts a robust manufacturing portfolio. This includes the production of a diverse range of drug delivery devices, such as prefilled syringes, various types of pen injectors, and autoinjectors. In addition to these drug-device combinations, they manufacture sterile injectables, soft gelatin capsules, and a variety of biologics solutions. Their manufacturing expertise extends to diverse biopharmaceutical modalities such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy products, and RNA-based therapeutics.
ONESOURCE's wide-ranging capabilities and integrated approach position it as a significant player in the global biopharmaceutical landscape. The company's commitment to quality and its broad service offering enable it to support the development and supply of a wide variety of biologics, contributing to advancements in healthcare both domestically and internationally. Its recent name change from Stelis Biopharma Limited to ONESOURCE Specialty Pharma Limited reflects a strategic shift towards highlighting its comprehensive and integrated service offering to clients.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Onesource Specialty Pharma Limited (ONESOURCE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Onesource Specialty Pharma Limited (ONESOURCE)?
The current share price of Onesource Specialty Pharma Limited (ONESOURCE) is ₹1,731.3. Today, the stock has gained by ₹42.40 (2.51%), trading in a range of ₹1,672.1 to ₹1,750. The stock opened at ₹1,704.5 with a trading volume of 3,84,200 shares.
02Is Onesource Specialty Pharma Limited stock a good investment for long-term?
Onesource Specialty Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹19,856.65 crores, P/E ratio of -407.42, ROE of -1.09%, and ROCE of 0.57%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Onesource Specialty Pharma Limited stock?
The 52-week high price of Onesource Specialty Pharma Limited (ONESOURCE) is ₹2,026.5, while the 52-week low is ₹1,057. Currently trading at ₹1,731.3, the stock is 69.6% away from its 52-week low and 14.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Onesource Specialty Pharma Limited stock at the current price?
Whether to buy Onesource Specialty Pharma Limited stock at ₹1,731.3 depends on multiple factors. The stock is currently trading with a P/E ratio of -407.42 and P/B ratio of 3.40. Today's performance shows a gain of 2.51%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Onesource Specialty Pharma Limited and when is the next dividend?
Onesource Specialty Pharma Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,731.3, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Onesource Specialty Pharma Limited?
Onesource Specialty Pharma Limited's key financial metrics include: P/E Ratio: -407.42, P/B Ratio: 3.40, ROE: -1.09%, ROCE: 0.57%, Dividend Yield: 0.00%, EPS: ₹-6.45, Book Value: ₹507.4, and Debt-to-Equity: 0.26. The company's market cap stands at ₹19,856.65 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Onesource Specialty Pharma Limited stock performing today in the market?
Onesource Specialty Pharma Limited stock opened at ₹1,704.5 and is currently trading at ₹1,731.3, showing a gain of ₹42.40 (2.51%). The intraday high is ₹1,750 and low is ₹1,672.1. The trading volume stands at 3,84,200 shares, indicating moderate market participation today.
08What is the P/E ratio of Onesource Specialty Pharma Limited and what does it indicate?
Onesource Specialty Pharma Limited has a Price-to-Earnings (P/E) ratio of -407.42, which means investors are willing to pay ₹-407.42 for every ₹1 of earnings. With an EPS of ₹-6.45, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Onesource Specialty Pharma Limited (ONESOURCE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.